Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Debt to Equity: 2020-2022

  • SAB Biotherapeutics' Debt to Equity was N/A to $0.02 in Q4 2022 from the same period last year, while for Dec 2022 it was $0.02, marking a year-over-year change of. This contributed to the annual value of $0.02 for FY2022, which is N/A change from last year.
  • As of Q4 2022, SAB Biotherapeutics' Debt to Equity stood at $0.02, which was up 295.43% from $0.00 recorded in Q4 2020.
  • SAB Biotherapeutics' Debt to Equity's 5-year high stood at $0.02 during Q4 2022, with a 5-year trough of $0.00 in Q4 2020.
  • In the last 2 years, SAB Biotherapeutics' Debt to Equity had a median value of $0.01 in 2020 and averaged $0.01.